Director, Interim CEO
Joseph Mannello has served as a consultant since May 2015. From March 2013 to May 2015, he served as the executive managing director at Brean Capital LLC, an independent investment bank and asset management firm, where he also served as a member of the firm’s operating committee. From March 2008 to March 2012, Mr. Mannello was the head of corporate credit for Gleacher & Company, Inc. (OTC:GLCH), a publicly-traded investment bank. Prior to that, he was the head of the fixed income division of BNY Capital Markets, Inc., a subsidiary of The Bank of New York Mellon Corp. (NYSE:BK). We believe Mr. Manello’s extensive financial markets background qualifies him to serve on our Board of Directors.
Joseph DiPietro joined Myos in September 2016. Mr. DiPietro was most recently the CFO at the Harlem School of the Arts in New York. He graduated St. John’s University in 1988 with a BS in Accounting. He obtained his CPA license while working as an auditor for McGladrey (RSM). He has held positions such as VP Finance, Controller, and Director of Financial Reporting at a few public companies such as Pfizer, Celgene, Juno Online, Majesco, Audible and Turtle Beach.
Science & Technology
Maghsoud Dariani has over 30 years of diverse and progressive management experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani has a successful record of business management, strategic planning, acquisition and divestiture, project management, production management, R&D management, economic evaluations, competitor analyses, and development and administration of multi-million dollar budgets. Mr. Dariani is also an entrepreneurial business leader with a sound grasp of successful business strategies, with an excellent foundation in science and engineering, and a strong background in product development and commercialization. As President & CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer, Mr. Dariani is responsible for overall management of the business and R&D, as well as securing capital for operations. Prior to joining Semorex, Mr. Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage then successfully negotiated the sale of the company in February 2003. Prior to Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, Mr. Dariani developed and implemented Celgene’s manufacturing strategy, managed and successfully sold Celgene’s chiral intermediates business unit, and formulated a strategic plan for leveraging Celgene’s expertise in chiral technologies towards the development of chirally pure drug products. Mr. Dariani was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names. Prior to Celgene, Mr. Dariani held progressively more responsible engineering and development positions at Celanese Corporation. Mr. Dariani holds a BS degree from The City College of NY and a MS degree from University of Massachusetts in Chemical Engineering. Mr. Dariani is a member of Board of Directors at Semorex Inc. and Mesa Therapeutics.
Executive VP of Sales and Marketing
Dominick Commesso joined
Neerav Dilip Padliya, PhD, PMP
Vice President, Research Alliances
Neerav Dilip Padliya, PhD, PMP is Vice President, Research Alliances at MYOS RENS Technology Inc. His career success began in 2006 at Celgene Corporation where he was the Principal Investigator behind a highly interdisciplinary program focused on mass spectrometry-based proteomic studies of placenta-derived populations of stem cells and natural killer cells. Dr. Padliya spearheaded collaborations with Immunologists and Cell Biologists that led to the issue of two U.S. patents, one pending U.S. patent application and the publication of one journal article as senior author. In 2011, Dr. Padliya joined AB SCIEX, (a wholly owned operating company of Danaher Corporation) a premier manufacturer of high-end mass spectrometry instrumentation used for applications in pharmaceuticals, clinical laboratories, environmental monitoring and the food and beverage industry. Prior to joining MYOS RENS Technology Inc., Dr. Padliya worked closely with the North American Sales Force at AB SCIEX to perform several winning demonstrations of accurate mass, high-resolution mass spectrometers that paved the way for new business opportunities with major pharmaceutical and biotechnology accounts. Dr. Padliya graduated with a B.Sc. (Honors), Chemistry in 2001 from McMaster University (Canada) and graduated with a PhD in Analytical Chemistry in 2005 from the State University of New York at Buffalo (USA). Dr. Padliya is the author of five peer-reviewed publications as first author and an inventor on two U.S. patents and one pending U.S. patent application. Dr. Padliya has served as a reviewer for well-reputed journals such as Anal. Chimica Acta, Anal. Methods, Integrative Biology, and Molecular Biosystems.
Operations, Facility Development Manager, Special Projects
Ms. Goodford has more than 25 years of management experience, with six years in project operations during contract start-up phases on government initiatives in a healthcare setting. Her role included office facilities build-outs, floor plan development, quality assurance, establishing processes and workflows, recruiting, hiring and training of staff. Ms. Goodford also served on several proposal development teams which had a 100% win rate and included responding to a $350m contract for the state of Georgia.
With an eye to quality outcomes, timely project completion and cost management, Ms. Goodford served as Project Manager for the build-out of MYOS RENS’ corporate offices bringing the project in under budget and under deadline. Ms. Goodford holds a BS from Montclair State University.
Quality Assurance Manager
Mr. Tess is responsible for implementing and maintaining the effectiveness of the quality system at MYOS RENS Technology Inc. He successfully runs programs that ensure all specifications for products or services are met and monitors progress and compliance through regular inspections. Mr. Tess develops standard operating procedures and manages stability studies, ensuring compliance with protocols. Prior to joining MYOS RENS Technology Inc., Mr. Tess worked as a research associate at Celgene Cellular Therapeutics exploring platforms for cell-based therapies in the therapeutic areas of cancer and inflammatory diseases. He excelled in establishing methods for differentiation of various cell lines form mesenchymal stem cells as well as characterizing and monitoring cell lines for comprehensive in vitro studies. Mr. Tess has a BS in Biochemistry from Fairleigh Dickinson University as well as a BS degree from Kazan Aviation University in Aircraft Engineering. In addition, Mr. Tess has completed Pharmaceutical Quality Assurance and Control Trainings.